Developer docs
API playgroundTry for free, no card

Search company profiles

Dicot Pharma

Full company profile

uuid0005eos

Namestring
Dicot Pharma
Legal namestring
Dicot AB (publ)
Websiteurl
dicotpharma.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Dicot Pharma AB (publ) is a Swedish clinical-stage pharmaceutical company founded in 2015 and headquartered in Uppsala, listed on Nasdaq First North Stockholm under the ticker DICOT since November 2024 (previously on Spotlight Stock Market from 2018). The company is developing a single drug candidate, LIB-01, intended to treat erectile dysfunction (ED) and premature ejaculation (PE). LIB-01 is positioned as the first new oral molecule class for ED in approximately 26 years (since Viagra), with Phase 2a data demonstrating improved erectile function persisting at least 28 days after the first dose, a substantial duration advantage over existing PDE5 inhibitors that require planning before each use. The molecule is protected by four patent families constituting a global IP strategy.

The company's strategy is to develop LIB-01 through Phase 2a under its own auspices and then out-license to larger pharmaceutical partners for Phase 3, registration, and global commercialization, generating revenue through upfront payments, development milestones, and royalties. Dicot is pre-revenue with no current customers or distribution channels; financing to date has come from multiple oversubscribed rights issues (2023, 2024, 2026), a directed guarantor share issue (2024), warrant exercises (TO6 in 2025), and a small Almi Uppsala grant (2023), cumulatively exceeding SEK 450 million. Clinical execution is anchored by Lead Principal Investigator Dr. Harin Padma-Nathan, the original PI for the Viagra and Cialis programs with 110+ clinical trials experience, and a global CRO engaged in December 2025 to run the planned Phase 2b study in the USA and Europe starting in late 2026.

Dicot's go-to-market is therefore licensing-led rather than commercial: the company targets partnership-driven value creation rather than building its own sales infrastructure. The Phase 2b study is the next major catalyst, after which management has signaled it will seek strategic alliances to finance and execute late-stage development and commercialization. With a lean organization of 1-10 employees centered on CEO Elin Trampe, CFO Björn Petersson, CSO Charlotta Gauffin, CBO Håkan Wickholm, CTO Mats Silvander, and Chairman Eva Sjökvist Saers, the company operates as a virtual clinical-development platform focused on de-risking LIB-01 to a partner-acquirable inflection point.

Short descriptiontext

Dicot Pharma is a Swedish clinical-stage pharmaceutical company developing LIB-01, a novel oral drug candidate targeting erectile dysfunction and premature ejaculation, planning to out-license for global commercialization following Phase 2a.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
erectile dysfunction treatment, sexual dysfunction therapeutics, pharmaceutical clinical trials, drug candidate development, men's health medicine
Industry1 code
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Erectile Dysfunction Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Licensing Royalties
TypeLicensing Royalties
Description

Dicot Pharma plans to generate revenue through licensing agreements with larger pharmaceutical companies. The company aims to out-license LIB-01 after demonstrating proof-of-concept, receiving upfront payments, milestone payments, and ongoing royalties from commercialization.

dicotpharma.com
2Strategic Pharma Partnerships
TypeLicensing Royalties
Description

The company seeks strategic alliances with established pharmaceutical companies that can finance and conduct late-stage clinical development and global commercialization of LIB-01.

dicotpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Dicot Pharma is developing LIB-01, a single patented drug candidate for the treatment of erectile dysfunction and premature ejaculation. The compound completed Phase 1 with a positive safety profile and an efficacy signal showing improved erectile function persisting 28 days after first dose, with a planned Phase 2b study in the USA and Europe starting in late 2026. The company plans to out-license LIB-01 to larger pharmaceutical companies for late-stage clinical development, registration, and global commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 50% of men with ED discontinue current treatments
+2 more records
Product overview1 text field

Dicot Pharma is a pharmaceutical company developing a single drug candidate, LIB-01, as a next-generation treatment for sexual dysfunctions including erectile dysfunction and premature ejaculation. The company's product portfolio consists of this one lead compound in clinical development, with the goal of bringing LIB-01 through clinical trials to become a registered pharmaceutical product globally.

Product and service1 record
1LIB-01
CategoryErectile Dysfunction Therapeutics
Description

Drug candidate being developed for the treatment of erectile dysfunction and premature ejaculation. LIB-01 is Dicot Pharma's single lead pharmaceutical asset, designed to deliver a longer duration of action and improved safety profile compared with existing oral erectile dysfunction treatments.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-12-18
Description

Dicot Pharma signed an agreement with a global CRO firm to conduct the Phase 2b clinical study for its erectile dysfunction drug candidate LIB-01. The study is expected to start in late 2026 and will be conducted in the USA and Europe.

2Dr. Harin Padma-Nathan
Strategic tierCoreTypeOthers
Description

World leading medical expert in male sexual dysfunctions serving as Lead Principal Investigator for over 110 clinical trials including the Viagra and Cialis programs. Currently serving as Principal Investigator for LIB-01 clinical studies.

dicotpharma.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

US specialty pharma commercializing KYZATREX, an oral testosterone replacement therapy for hypogonadism. Comparable as a small, men's-health-focused pharma pursuing urology and men's health prescribing channels overlapping with LIB-01's target prescriber base.

TypeBroad incumbent
Description

Specialty pharma that commercialized avanafil (Stendra) for erectile dysfunction. Comparable as an ED-focused pharma player with experience in PDE5-related commercialization, regulatory pathway, and urology sales channels relevant to LIB-01's eventual launch.

TypeOthers
Description

Large-cap pharma with established consumer health and specialty care channels that could plausibly partner or acquire a novel ED asset like LIB-01. Included as a representative big-pharma potential acquirer/partner given the out-licensing strategy Dicot has explicitly disclosed.

TypeBroad incumbent
Description

Global leader in urology and men's health medical devices (including penile implants). Comparable as an established player in the broader ED treatment ecosystem with deep urology channel relationships relevant to any eventual LIB-01 commercialization partner.

TypeBroad incumbent
Description

Originator of sildenafil (Viagra), the dominant PDE5 inhibitor that LIB-01 is designed to compete against. Pfizer's urology franchise, ED clinical evidence base, and physician relationships set the competitive benchmark LIB-01 must surpass.

TypeDirect peer
Description

Developed Vitaros (alprostadil cream) for erectile dysfunction and was structured as a small clinical/specialty pharma focused on out-licensing and partnership-based commercialization — a near-analog business model to Dicot's planned LIB-01 path.

TypeDirect peer
Description

UK-listed clinical-stage company developing Eroxon (MED2002), a topical gel for erectile dysfunction. Highly comparable as a small-cap, single-asset ED developer pursuing regulatory approval and commercialization partnerships in the same indication as Dicot's LIB-01.

TypeBroad incumbent
Description

Marketer of vardenafil (Levitra), a PDE5 inhibitor with established urology sales infrastructure and direct ED clinical experience. Bayer serves as a representative big-pharma comparator and a likely acquirer/partner candidate for novel ED assets.

TypeEmerging player
Description

Developer of Promescent (lidocaine spray) for premature ejaculation. Comparable as a small, focused sexual-health therapeutics company addressing the second indication LIB-01 targets, sharing similar end markets and physician specialties.

TypeBroad incumbent
Description

Originator of tadalafil (Cialis), the second major PDE5 inhibitor and the standard-of-care comparator in most modern ED clinical trials. Lilly's lifecycle management of Cialis through combination and OTC pivots frames the competitive landscape LIB-01 enters.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dicot Pharma

Erectile Dysfunction Therapeuticsdicotpharma.com

Dicot Pharma is a Swedish clinical-stage pharmaceutical company developing LIB-01, a novel oral drug candidate targeting erectile dysfunction and premature ejaculation, planning to out-license for global commercialization following Phase 2a.

What Dicot Pharma does

Dicot Pharma AB (publ) is a Swedish clinical-stage pharmaceutical company founded in 2015 and headquartered in Uppsala, listed on Nasdaq First North Stockholm under the ticker DICOT since November 2024 (previously on Spotlight Stock Market from 2018). The company is developing a single drug candidate, LIB-01, intended to treat erectile dysfunction (ED) and premature ejaculation (PE). LIB-01 is positioned as the first new oral molecule class for ED in approximately 26 years (since Viagra), with Phase 2a data demonstrating improved erectile function persisting at least 28 days after the first dose, a substantial duration advantage over existing PDE5 inhibitors that require planning before each use. The molecule is protected by four patent families constituting a global IP strategy.

The company's strategy is to develop LIB-01 through Phase 2a under its own auspices and then out-license to larger pharmaceutical partners for Phase 3, registration, and global commercialization, generating revenue through upfront payments, development milestones, and royalties. Dicot is pre-revenue with no current customers or distribution channels; financing to date has come from multiple oversubscribed rights issues (2023, 2024, 2026), a directed guarantor share issue (2024), warrant exercises (TO6 in 2025), and a small Almi Uppsala grant (2023), cumulatively exceeding SEK 450 million. Clinical execution is anchored by Lead Principal Investigator Dr. Harin Padma-Nathan, the original PI for the Viagra and Cialis programs with 110+ clinical trials experience, and a global CRO engaged in December 2025 to run the planned Phase 2b study in the USA and Europe starting in late 2026.

Dicot's go-to-market is therefore licensing-led rather than commercial: the company targets partnership-driven value creation rather than building its own sales infrastructure. The Phase 2b study is the next major catalyst, after which management has signaled it will seek strategic alliances to finance and execute late-stage development and commercialization. With a lean organization of 1-10 employees centered on CEO Elin Trampe, CFO Björn Petersson, CSO Charlotta Gauffin, CBO Håkan Wickholm, CTO Mats Silvander, and Chairman Eva Sjökvist Saers, the company operates as a virtual clinical-development platform focused on de-risking LIB-01 to a partner-acquirable inflection point.

Dicot Pharma firmographics

Firmographics
Name
Dicot Pharma
Legal name
Dicot AB (publ)
Website
https://dicotpharma.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Dicot Pharma is a Swedish clinical-stage pharmaceutical company developing LIB-01, a novel oral drug candidate targeting erectile dysfunction and premature ejaculation, planning to out-license for global commercialization following Phase 2a.
Ownership category
akta.pro rank

Dicot Pharma industry classification

Industry
Product category
Erectile Dysfunction Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Erectile dysfunction treatment
  • Sexual dysfunction therapeutics
  • Pharmaceutical clinical trials
  • Drug candidate development
  • Men's health medicine

Where Dicot Pharma is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Dicot Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Licensing Royalties: Dicot Pharma plans to generate revenue through licensing agreements with larger pharmaceutical companies. The company aims to out-license LIB-01 after demonstrating proof-of-concept, receiving upfront payments, milestone payments, and ongoing royalties from commercialization.
  2. Strategic Pharma Partnerships: The company seeks strategic alliances with established pharmaceutical companies that can finance and conduct late-stage clinical development and global commercialization of LIB-01.

Go-to-market motion2 records

Marketing channels4 records

Dicot Pharma product offering

Product offering

Core offering

Dicot Pharma is developing LIB-01, a single patented drug candidate for the treatment of erectile dysfunction and premature ejaculation. The compound completed Phase 1 with a positive safety profile and an efficacy signal showing improved erectile function persisting 28 days after first dose, with a planned Phase 2b study in the USA and Europe starting in late 2026. The company plans to out-license LIB-01 to larger pharmaceutical companies for late-stage clinical development, registration, and global commercialization.

Product overview

Dicot Pharma is a pharmaceutical company developing a single drug candidate, LIB-01, as a next-generation treatment for sexual dysfunctions including erectile dysfunction and premature ejaculation. The company's product portfolio consists of this one lead compound in clinical development, with the goal of bringing LIB-01 through clinical trials to become a registered pharmaceutical product globally.

Differentiator

Problem solved

Functional benefit

Products and services

  • LIB-01 Drug candidate being developed for the treatment of erectile dysfunction and premature ejaculation. LIB-01 is Dicot Pharma's single lead pharmaceutical asset, designed to deliver a longer duration of action and improved safety profile compared with existing oral erectile dysfunction treatments.

Quantifiable outcome

  • 50% of men with ED discontinue current treatments
  • +2 more outcomes

Companies that use Dicot Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Dicot Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Dicot Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Global CRO (Contract Research Organization)coreImplementation/ SI/ Consulting Partner · 18 December 2025Dicot Pharma signed an agreement with a global CRO firm to conduct the Phase 2b clinical study for its erectile dysfunction drug candidate LIB-01. The study is expected to start in late 2026 and will be conducted in the USA and Europe.
  • Dr. Harin Padma-NathancoreOthersWorld leading medical expert in male sexual dysfunctions serving as Lead Principal Investigator for over 110 clinical trials including the Viagra and Cialis programs. Currently serving as Principal Investigator for LIB-01 clinical studies.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Dicot Pharma competitors and assessment

Company assessment

Emerging players

  • Marius Pharmaceuticals: US specialty pharma commercializing KYZATREX, an oral testosterone replacement therapy for hypogonadism. Comparable as a small, men's-health-focused pharma pursuing urology and men's health prescribing channels overlapping with LIB-01's target prescriber base.
  • Absorption Pharmaceuticals: Developer of Promescent (lidocaine spray) for premature ejaculation. Comparable as a small, focused sexual-health therapeutics company addressing the second indication LIB-01 targets, sharing similar end markets and physician specialties.

Broad incumbents

  • VIVUS: Specialty pharma that commercialized avanafil (Stendra) for erectile dysfunction. Comparable as an ED-focused pharma player with experience in PDE5-related commercialization, regulatory pathway, and urology sales channels relevant to LIB-01's eventual launch.
  • Coloplast: Global leader in urology and men's health medical devices (including penile implants). Comparable as an established player in the broader ED treatment ecosystem with deep urology channel relationships relevant to any eventual LIB-01 commercialization partner.
  • Pfizer (Viagra): Originator of sildenafil (Viagra), the dominant PDE5 inhibitor that LIB-01 is designed to compete against. Pfizer's urology franchise, ED clinical evidence base, and physician relationships set the competitive benchmark LIB-01 must surpass.
  • Bayer (Levitra): Marketer of vardenafil (Levitra), a PDE5 inhibitor with established urology sales infrastructure and direct ED clinical experience. Bayer serves as a representative big-pharma comparator and a likely acquirer/partner candidate for novel ED assets.
  • Eli Lilly (Cialis): Originator of tadalafil (Cialis), the second major PDE5 inhibitor and the standard-of-care comparator in most modern ED clinical trials. Lilly's lifecycle management of Cialis through combination and OTC pivots frames the competitive landscape LIB-01 enters.

Others

  • Sanofi: Large-cap pharma with established consumer health and specialty care channels that could plausibly partner or acquire a novel ED asset like LIB-01. Included as a representative big-pharma potential acquirer/partner given the out-licensing strategy Dicot has explicitly disclosed.

Direct peers

  • Apricus Biosciences: Developed Vitaros (alprostadil cream) for erectile dysfunction and was structured as a small clinical/specialty pharma focused on out-licensing and partnership-based commercialization — a near-analog business model to Dicot's planned LIB-01 path.
  • Futura Medical: UK-listed clinical-stage company developing Eroxon (MED2002), a topical gel for erectile dysfunction. Highly comparable as a small-cap, single-asset ED developer pursuing regulatory approval and commercialization partnerships in the same indication as Dicot's LIB-01.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Dicot Pharma social profiles

Digital presence

Dicot Pharma compliance and trust

Trust signal

Compliance1 record

Dicot Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dicot Pharma leadership team

Management profile

Number of profiles

Profiles6 records

Dicot Pharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dicot Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dicot Pharma

What does Dicot Pharma do?

Dicot Pharma is developing LIB-01, a single patented drug candidate for the treatment of erectile dysfunction and premature ejaculation. The compound completed Phase 1 with a positive safety profile and an efficacy signal showing improved erectile function persisting 28 days after first dose, with a planned Phase 2b study in the USA and Europe starting in late 2026. The company plans to out-license LIB-01 to larger pharmaceutical companies for late-stage clinical development, registration, and global commercialization.

Is Dicot Pharma a public or private company?

Dicot Pharma is a public company. It is classified as public and is currently operating.

When was Dicot Pharma founded?

Dicot Pharma was founded in 2015. It employs 1 to 10 people.

Where is Dicot Pharma based?

Dicot Pharma is headquartered in Uppsala, Sweden, in the Europe region.

How does Dicot Pharma make money?

Two revenue lines are on record. Pharmaceutical Licensing Royalties are the primary driver. The others are strategic Pharma Partnerships.

Who are Dicot Pharma's main competitors?

Emerging players on record are Marius Pharmaceuticals and Absorption Pharmaceuticals. Broad incumbents are VIVUS, Coloplast, Pfizer (Viagra), Bayer (Levitra) and Eli Lilly (Cialis). Sanofi is listed as an others. Direct peers are Apricus Biosciences and Futura Medical.

Does Dicot Pharma have an API?

No public API is recorded for Dicot Pharma.

What industry is Dicot Pharma in?

Dicot Pharma's product category is Erectile Dysfunction Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewDicot Pharma AB (DICOT) Receives EU Approval for LIB-01 Phase 2b StudyDicot Pharma received EU approval to conduct its LIB-01 phase 2b study in Sweden, the first EU country to grant approval. Dosing in the EU for part II can begin after part I is completed in the US, expected in Q1 2027. The trial plans at least 200 participants and will inform dose selection for phase 3.MarketScreenerDicot Pharma to present three LIB-01 abstracts at US conferenceDicot Pharma announced that three abstracts regarding its drug candidate LIB-01 were selected for oral presentation at the Sexual Medicine Society of North America's congress in Orlando. The presentations will cover the drug's mechanism of action, positive Phase 2a results, and the design for a subsequent Phase 2b study. This selection highlights scientific interest in LIB-01 as a potential new treatment for erectile dysfunction.MarketScreenerDicot Pharma Names Cecilia Driving as New CFODicot Pharma appointed Cecilia Driving as its new CFO. Driving previously served as CFO of W5 Solutions. The appointment was announced on 07/01/2026.MarketScreenerDicot Pharma gets FDA clearance for first part of phase 2b studyDicot Pharma received FDA clearance to start the first part of its phase 2b study, which will determine the highest dose for the efficacy portion. The company must obtain additional toxicology data to launch the second part in the US, moving up a planned preclinical study. An application to start the study in Europe is expected in the third quarter, with the study start in the second half of 2026 unchanged.BioWorldFinancings for June 10, 2026On June 10, 2026, biopharma and med-tech companies including Aim Immunotech, Antogen, Cerus, City, Corvus, Dicot, Eloxx, Ideaya, Idorsia, Shattuck, and Starton raised money through public or private financings. The list covers both public and private financing activities.BioWorldFinancings for June 8, 2026On June 8, 2026, biopharma and med-tech companies including Dicot, Iqvia, Nrx, Seres, and Vivos raised funds through public or private financings. The list of companies is provided in the BioWorld brief.BiostockDicot Pharma's share issue oversubscribedDicot Pharma's share issue oversubscribed at approximately 126% of the guarantee level, providing about SEK 210 million before issue costs. The company plans a directed issue of up to SEK 21 million to fund development of its erectile dysfunction drug candidate LIB-01. The final issue outcome is expected around June 9.MarketScreenerDicot Pharma Signs Agreement with CRO Firm for Phase 2b StudyDicot Pharma has signed an agreement with a global contract research organization (CRO) to prepare for a Phase 2b clinical study of its drug candidate LIB-01 for erectile dysfunction. The study will be conducted in the USA and Europe and is expected to begin in the second half of 2026. The CEO stated that the CRO was selected for its extensive experience in contract research and specific expertise in the therapeutic area of erectile dysfunction.news.cision.comDicot Pharma AB publishes prospectus in connection with the upcoming rights issueDicot Pharma AB has published an EU growth prospectus for a rights issue of shares and warrants, which was approved by the Swedish Financial Supervisory Authority. The company intends to raise approximately SEK 122.6 million to finance a clinical phase 2a study for its drug candidate LIB-01 and prepare for subsequent phase 2b studies.